Literature DB >> 9873820

Telomerase is strongly activated in hepatocellular carcinoma but not in chronic hepatitis and cirrhosis.

Y M Park1, J Y Choi, B H Byun, C H Cho, H S Kim, B S Kim.   

Abstract

Telomerase is highly activated in human immortal cell lines and tumor tissues, whereas it is not activated in primary cell strains and many tumor-adjacent tissues. It is suggested that telomerase activation is one of the critical steps in malignant transformation. In the present study, the telomerase activity was investigated in hepatocellular carcinoma tissues and non-tumor liver tissues from Korean patients with chronic hepatitis and cirrhosis. Eighty two liver tissues (24 chronic hepatitis specimens, 34 cirrhosis specimens, and 24 hepatocellular carcinomas) were obtained from 23 chronic viral hepatitis patients, 19 cirrhosis patients (including 7 liver transplants), and 24 patients with hepatocellular carcinoma, of which the surrounding non-tumor liver tissues were available in 16 patients (1 chronic hepatitis and 15 cirrhosis). As negative controls, 3 normal liver tissues were included. Protein from liver specimens was purified by a detergent lysis method as described elsewhere, and telomerase activity was measured in 2 diluents of each sample (1:1 and 1:100) by a telomeric repeat amplification protocol (TRAP). Telomerase was strongly activated in 79% (19/24) of the hepatocellular carcinomas, while weakly in 8% (2/24) of the chronic hepatitis tissues and in 24% (8/34) of the cirrhosis tissues. All of 3 normal control livers showed no telomerase activation. No relationship could be observed between the enhancement of telomerase activity and tumor nature. None of the chronic heaptitis or cirrhosis patients with mild telomerase activation in the liver have developed hepatocellular carcinoma for at least 2 years of follow-up period. These results suggest that the strong enhancement of telomerase activity may be a critical part of hepatocarcinogenesis, although the exact mechanism of such high activation in hepatocellular carcinoma is not clear. In addition, further study will be necessary to clarify the reason why no telomerase activity detectable by a conventional TRAP can be seen in some hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9873820     DOI: 10.1038/emm.1998.5

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  6 in total

1.  Telomerase activity in peripheral blood mononuclear cells as a universal scale for quantitative measurement of telomerase activation on the example of liver diseases.

Authors:  D A Skvortsov; M A Ezhova; Y E Lourie; A V Metelin; I D Strazhesko; E N Dudinskaya; M A Kalinina; M E Zvereva; O A Dontsova; E F Kim
Journal:  Dokl Biochem Biophys       Date:  2015-07-12       Impact factor: 0.788

2.  Dynamic alteration of telomerase expression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma.

Authors:  Deng-Fu Yao; Wei Wu; Min Yao; Li-Wei Qiu; Xin-Hua Wu; Xiao-Qin Su; Li Zou; Deng-Bing Yao; Xian-Yong Meng
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

3.  Telomerase activity in tumor and remnant liver as predictor of recurrence and survival in hepatocellular carcinoma after resection.

Authors:  Yan-Shen Shan; Yu-Hsiang Hsieh; Pin-Wen Lin
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

4.  The regulation of telomerase in oncogenesis.

Authors:  D A Skvortzov; M P Rubzova; M E Zvereva; F L Kiselev; O A Donzova
Journal:  Acta Naturae       Date:  2009-04       Impact factor: 1.845

5.  The combination of TRAIL treatment and cancer cell selective expression of TRAIL-death receptor DR4 induces cell death in TRAIL-resistant cancer cells.

Authors:  Eunah Choi; Youngtae Kim; Kunhong Kim
Journal:  Yonsei Med J       Date:  2006-02-28       Impact factor: 2.759

Review 6.  Autophagy: The multi-purpose bridge in viral infections and host cells.

Authors:  Asghar Abdoli; Mehrdad Alirezaei; Parvaneh Mehrbod; Faezeh Forouzanfar
Journal:  Rev Med Virol       Date:  2018-04-30       Impact factor: 6.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.